Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Pinter, M; Hucke, F; Graziadei, I; Vogel, W; Maieron, A; Königsberg, R; Stauber, R; Grünberger, B; Müller, C; Kölblinger, C; Peck-Radosavljevic, M; Sieghart, W.
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Radiology. 2012; 263(2):590-599 Doi: 10.1148/radiol.12111550 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Stauber Rudolf
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Purpose: To compare the efficacies of transarterial chemoembolization (TACE) and sorafenib in patients with advanced-stage hepatocellular carcinoma (HCC). Materials and Methods: The retrospective analysis of the data was approved by the institutional review board; the requirement to obtain informed consent was waived. Three hundred seventy-two patients with HCC were treated between January 1999 and December 2009. Patients with advanced HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging classification (Child-Pugh class A or B, Eastern Cooperative Oncology Group performance status of 1-2, and/or macrovascular invasion or extrahepatic metastasis) were included in the study (n = 97). Thirty-four patients underwent conventional TACE with doxorubicin plus lipiodol or TACE with drug-eluting beads; 63 patients were treated with sorafenib. Results: The median duration of sorafenib treatment was 4.6 months (95% confidence interval [CI]: 3.2, 6.0 months). The median number of TACE sessions per patient was 3 +/- 2. Side effects of TACE and sorafenib were comparable to those reported in the literature. The median time to progression was similar between the two treatment groups (P = .737). The median overall survival was 9.2 months (95% CI: 6.1, 12.3 months) for patients treated with TACE and 7.4 months (95% CI: 5.6, 9.2 months) for those treated with sorafenib (P = .377). Only Child-Pugh class was associated with a better overall survival at uni- and multivariate analysis. Conclusion: TACE achieved a promising outcome in select patients with advanced HCC (BCLC stage C). (C) RSNA, 2012
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Antineoplastic Agents - administration and dosage Antineoplastic Agents - adverse effects; Benzenesulfonates - administration and dosage Benzenesulfonates - adverse effects; Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy; Chemoembolization, Therapeutic - methods; Chi-Square Distribution -; Contrast Media - administration and dosage; Disease Progression -; Doxorubicin - administration and dosage Doxorubicin - adverse effects; Ethiodized Oil - administration and dosage Ethiodized Oil - adverse effects; Female -; Humans -; Liver Neoplasms - pathology Liver Neoplasms - therapy; Magnetic Resonance Imaging -; Male -; Middle Aged -; Neoplasm Staging -; Proportional Hazards Models -; Pyridines - administration and dosage Pyridines - adverse effects; Retrospective Studies -; Survival Analysis -; Tomography, X-Ray Computed -; Treatment Outcome -; Tumor Markers, Biological - analysis